🔎 Trials Near Me

Home › Diffuse Large B-Cell Lymphoma › Arizona

Diffuse Large B-Cell Lymphoma clinical trials in Arizona

13 studies for Diffuse Large B-Cell Lymphoma are looking for participants at sites in Arizona.

Cities in Arizona

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

  • Honor Health Research Institute, Scottsdale
  • University of Arizona Cancer Center, Tucson
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT05006716

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

  • Ironwood Cancer & Research Centers ( Site 0204), Chandler
  • Palo Verde Cancer Specialists ( Site 0105), Glendale
  • City of Hope - Phoenix ( Site 0202), Goodyear
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06890884

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

  • Palo Verde Hematology/ Oncology Center, Ltd. ( Site 0175), Glendale
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05139017

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

  • Banner MD Anderson Cancer Center ( Site 0165), Gilbert
  • Banner MD Anderson Cancer Center - University Medical Center Phoenix ( Site 0167), Phoenix
  • The University of Arizona Cancer Center - North Campus ( Site 0124), Tucson
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06717347

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

  • Mayo Clinic - Scottsdale, Scottsdale
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07226843

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

  • Banner MD Anderson Cancer Center, Gilbert
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 31, 2026 · NCT06500273

Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU

  • Banner MD Anderson Cancer Center, Gilbert
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 5, 2026 · NCT06116110

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

  • Banner MD Anderson Cancer Center, Gilbert
  • Honor Health, Scottsdale
  • Mayo Clinic Arizona, Scottsdale
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 4, 2026 · NCT07188558

DALY II USA/ MB-CART2019.1 for DLBCL

  • Banner MD Anderson Cancer Center, Gilbert
  • Mayo Clinic, Phoenix
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 13, 2026 · NCT04792489

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

  • Banner University Medical Center - Tucson, Tucson
  • University of Arizona Cancer Center-North Campus, Tucson
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Feb 2, 2026 · NCT05633615

Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

  • Mayo Clinic in Arizona, Scottsdale
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jan 28, 2026 · NCT06834373

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

  • Banner University Medical Center - Tucson, Tucson
  • University of Arizona Cancer Center-North Campus, Tucson
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 20, 2025 · NCT05890352

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.